Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $61.9 million.

  • Centessa Pharmaceuticals' Cash from Investing Activities rose 3776.58% to $61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.4 million, marking a year-over-year decrease of 136066.79%. This contributed to the annual value of $31.3 million for FY2024, which is 12461.89% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Cash from Investing Activities is $61.9 million, which was up 3776.58% from -$40.0 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Cash from Investing Activities peaked at $61.9 million during Q3 2025, and registered a low of -$222.4 million during Q1 2025.
  • Moreover, its 4-year median value for Cash from Investing Activities was -$240000.0 (2022), whereas its average is -$19.8 million.
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Cash from Investing Activities showed a top increase of 30451250.0% in 2023 and a maximum decrease of 3587333.33% in 2023.
  • Centessa Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$446000.0 in 2022, then crashed by 3997.53% to -$18.3 million in 2023, then skyrocketed by 236.8% to $25.0 million in 2024, then skyrocketed by 147.78% to $61.9 million in 2025.
  • Its last three reported values are $61.9 million in Q3 2025, -$40.0 million for Q2 2025, and -$222.4 million during Q1 2025.